Download PDF
Thromb Haemost 1997; 77(03): 526-534
DOI: 10.1055/s-0038-1656001
Fibrinolysis
Schattauer GmbH Stuttgart

Inhibition of Urokinase-type Plasminogen Activator (uPA) Abrogates Myogenesis In Vitro

Pura Muñoz-Cánoves
1   The Departament de Receptors Cel. lulars, Institut de Recerca Oncològica (IRO), Barcelona, Spain
,
Francesc Miralles
1   The Departament de Receptors Cel. lulars, Institut de Recerca Oncològica (IRO), Barcelona, Spain
2   The Departament Unitat de Genètica Molecular, Hospital de Sant Pau, Barcelona, Spain
,
Montserrat Baiget
2   The Departament Unitat de Genètica Molecular, Hospital de Sant Pau, Barcelona, Spain
,
Jordi Félez
1   The Departament de Receptors Cel. lulars, Institut de Recerca Oncològica (IRO), Barcelona, Spain
› Author Affiliations
Further Information

Publication History

Received 18 July 1996

Accepted after resubmission 14 November 1996

Publication Date:
11 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Urokinase-type plasminogen activator (uPA) is one of the components of blood’s fibrinolytic cascade. uPA acts as a broad spectrum proteolytic enzyme involved in different physio-pathological processes including cellular fibrinolysis, adhesion, migration, invasion and remodeling. Here, we present evidence that uPA participates in myogenesis, a process which requires drastic cell membrane reorganization, leading to the plurinucleated myotube from the progenitor myoblast. We have dissected the expression of uPA throughout the different myogenic compartments and found an increase in uPA enzymatic activity associated with myotube formation in C2C12 myoblast cells, with uPA mRNA increasing prior the onset of fusion and differentiation. When both fusion and differentiation were blocked by specific inhibitors (DMSO, cyto-chalasin B) the levels of uPA were strongly downregulated. This process was reversible and specific: the removal of the inhibitors immediately restored the levels of uPA mRNA while the specific inhibition of uPA enzymatic activity by an anti-uPA antibody resulted in a 50% reduction of the extent of fusion and in the abrogation of muscle-specific gene products, such as a-actin and MyoD. Moreover, the conversion of fibroblasts to muscle-like cells upon acquisition of MyoD resulted in a dramatic increase of uPA mRNA, which was partially due to transcriptional activation of the uPA gene. These results indicate that the increase in uPA expression prior to fusion and differentiation occurs via a MyoD-mediated mechanism whereas the normal MyoD expression requires the plasminogen activation-dependent activity of this protease. Therefore, these studies extend the sphere of influence of myogenic factors to fibrinolysis, an intrinsic component of the hematological system. Taken together, one mechanism used by the myoblast cell to become a differentiated myotube, involving the inductive extracellular proteolysis of urokinase, is proposed.

 

  • References

  • 1 Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-3124
    PubMedGoogle Scholar
  • 2 Lijnen HR, Collen D. Regulation and control of the fibrinolytic system. In: Serine proteases and their serpin inhibitors in the nervous system. Festoff BW. ed. Plenum Press; New York: 1990. pp 0009-0020
    CrossrefGoogle Scholar
  • 3 Mignatti P, Robbins E, Rifkin DB. Tumor invasion through the human amniotic membrane: Requirement for a proteinase cascade. Cell 1986; 47: 0487-0498
    CrossrefPubMedGoogle Scholar
  • 4 Anderson JM, Swenarchuk LE, Champaneria S. Localized extracellular proteolysis may convey inductive signals between nerve and muscle cells during synaptogenesis. In: Serine proteases and their inhibitors in the nervous system. Festoff BW. ed. Plenum Press; New York: 1990. pp 0255-0273
    Google Scholar
  • 5 Tienari J, Alanko T, Lehtonen E, Saksela O. The expression and localization of urokinase-type plasminogen activator and its type 1 inhibitor are regulated by retionic acid and fibroblast growth factor in human teratocarcinoma cells. Cell Regul 1991; 2: 0285-0297
    CrossrefPubMedGoogle Scholar
  • 6 Muñoz-Cánoves P, Félez J. Role of plasminogen activators in muscle regeneration. Biol Clin Hematol 1993; 15: 0163-0171
    PubMedGoogle Scholar
  • 7 Saksela O, Rifkin DB. Cell-associated plasminogen activation: Regulation and physiological functions. Ann Rev Cell Biol 1988; 4: 0093-0126
    CrossrefPubMedGoogle Scholar
  • 8 Carmeliet P, Collen D. Evaluation of the plasminogen/plasmin system in transgenic mice. Fibrinolysis 1994; 8 (Suppl. 01) 0269-0276
    PubMedGoogle Scholar
  • 9 Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, Van den Oord JJ, Collen D, Mulligan RC. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994; 368: 0419-0424
    CrossrefPubMedGoogle Scholar
  • 10 Carmeliet P, Bouché A, De Clercq C, Pollefeyt S, Wijns S, Mulligan RC, Collen D. Biological effects of disruption of the tissue-type plasminogen activator, urokinase type plasminogen activator and plasminogen activator inhibitor-1 genes in mice. Ann NY Acad Sci 1995; 7480: 0367
    PubMedGoogle Scholar
  • 11 Blau HM, Pavlath GK, Hardeman EC, Chiu Ch-P, Silberstein L, Webster SG, Miller SC, Webster C. Plasticity of the differentiated state. Science 1985; 230: 0758-0766
    CrossrefPubMedGoogle Scholar
  • 12 Mohun T. Muscle differentation. Curr Opin Cell Biol 1992; 4: 0923-0928
    CrossrefPubMedGoogle Scholar
  • 13 Olson EN. Interplay between proliferation and differentiation within the myogenic lineage. Dev Biol 1992; 154: 0261-0272
    CrossrefPubMedGoogle Scholar
  • 14 Sorrentino V, Pepperkok R, Davis RL, Ansorge W, Philipson L. Cell proliferation inhibited by MyoD1 independently of myogenic differentiation. Nature 1990; 345: 0813-0815
    CrossrefPubMedGoogle Scholar
  • 15 Trouche D, Grigoriev M, Lenormand J-L, Robin P, Leibovitch SA, Sassone-Corsi P, Harel-Bellan A. Repression of c-fos promoter by MyoD on muscle cell differentiation. Nature 1993; 363: 0079-0082
    CrossrefPubMedGoogle Scholar
  • 16 Fulton AB, Prives J, Farmer SR, Penman S. Developmental reorganization of the skeletal framework and its surface lamina in fusing muscle cells. J Cell Biol 1981; 91: 0103-0112
    CrossrefPubMedGoogle Scholar
  • 17 Weintraub H, Davis RL, Tapscott S, Thayer M, Krause M, Benezra R, Blackwell TK, Turner D, Rupp R, Hollenberg S, Zhuang Y, Lassar AB. The MyoD gene family: Nodal point during specification of the muscle cell lineage. Science 1991; 251: 0761-0766
    CrossrefPubMedGoogle Scholar
  • 18 Boukamp P, Fusenig NE. Trans-differentiation from epidermal to mesenchymal/myogenic phenotype is associated with a drastic change in cell-cell and cell-matrix adhesion molecules. J Cell Biol 1993; 120: 0981-0993
    CrossrefPubMedGoogle Scholar
  • 19 Weintraub H, Tapscott SJ, Davis RL, Thayer MJ, Adam MA, Lassar AB, Miller AD. Activation of muscle-specific genes in pigment, nerve, fat, liver, and fibroblast cell lines by forced expression of MyoD. Proc Natl Acad Sci USA 1989; 86: 5434-5438
    CrossrefPubMedGoogle Scholar
  • 20 Davis RL, Weintraub H, Lassar AB. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 1987; 51: 0987-1000
    CrossrefPubMedGoogle Scholar
  • 21 Bengal E, Ransone L, Scharfmann R, Dwarki VJ, Tapscott SJ, Weintraub H, Verma IM. Functional antagonism between c-jun and MyoD proteins: A direct physical association. Cell 1992; 68: 0507-0519
    CrossrefPubMedGoogle Scholar
  • 22 Li L, Chambard JC, Karin M, Olson EN. Fos and Jun repress transcriptonal activation by myogenin and MyoD: The amino terminus of Jun can mediate repression. Genes Dev 1992; 6: 0676-0689
    CrossrefPubMedGoogle Scholar
  • 23 Shimizu M, Webster C, Morgan DO, Blau HM, Roth RA. Insulin and insulinlike growth factor receptors and responses in cultured human muscle cells. Am J Physiol 1986; 251: E611-E615
    PubMedGoogle Scholar
  • 24 Hantai D, Soria C, Soria J, Blondet B, Barlovatz-Meimom G, Rao JS, Festoff BW. Plasminogen activators in development, injury and pathology of the neuromuscular system. In: Serine proteases and their inhibitors in the nervous system. Festoff BW. ed. Plenun Press; New York: 1991. pp 0219-0229
    Google Scholar
  • 25 Miskin R, Easton TG, Reich E. Plasminogen activator in chick embryo muscle cells: Induction of enzyme by RSV, PMA and retinoic acid. Cell 1978; 15: 1301-1312
    CrossrefPubMedGoogle Scholar
  • 26 Quax PHA, Frisdal E, Pedersen N, Bonavaud S, Thiberst PH, Martelly I, Verheijen JH, Blasi F, Barlovatz-Meimon G. Modulation of activities and RNA level of the components of the plasminogen activation system during fusion of human myogenic satellite cells in vitro. Dev Biol 1992; 151: 0166-0175
    CrossrefPubMedGoogle Scholar
  • 27 Belin D, Vassalli J-D, Combepine Ch, Godeau F, Nagamine Y, Reich E, Kocher HP, Duvoisin RM. Cloning, nucleotide sequencing and expression of cDNAs encoding mouse urokinase-type plasminogen activator. Eur J Biochem 1985; 148: 0225-0232
    CrossrefPubMedGoogle Scholar
  • 28 Hu MC-T, Sharp SB, Davidson D. The complete sequence of the mouse skeletal alpha-actin genes reveals several conserved and inverted repeat sequences outside of the protein coding region. Mol Cell Biol 1986; 6: 0015-0025
    CrossrefPubMedGoogle Scholar
  • 29 Sabath DE, Broome HE, Prystowsky MB. Glyceraldehyde-3-phosphate dehydrogenase mRNA is a major interleukin 2-induced trascript in a cloned T-helper lymphocyte. Gene 1990; 91: 0185-0191
    CrossrefPubMedGoogle Scholar
  • 30 Ben-Ze’ev A. Cell and muscle motility. Shay JW. ed. Plenum Press; New York: 1985. pp 0023-0053
    CrossrefGoogle Scholar
  • 31 Longstaff C, Clough AM, Gaffney PJ. Kinetics of plasmin activation of single chain urinary-type plasminogen activator (scu-PA) and demonstration of a high affinity interaction between scu-PA and plasminogen. J Biol Chem 1992; 267: 0173-0179
    PubMedGoogle Scholar
  • 32 Longstaff C. In vivo significance of kinetic constants of tight binding reversible proteinase inhibitors. Thromb Haemost 1992; 67: 0533-0536
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Yaffe D, Saxel O. Serial passaging and differentation of myogenic cells isolated from dystrophic mouse muscle. Nature 1977; 270: 0725-0727
    CrossrefPubMedGoogle Scholar
  • 34 Blau HM, Chiu Ch-P, Webster C. Cytoplasmic activation of human nuclear genes in stable heterocaryons. Cell 1983; 32: 1171-1180
    CrossrefPubMedGoogle Scholar
  • 35 Devlin RB, Emerson CP. Coordinate regulation of contractile protein synthesis during myoblast differentiation. Cell 1978; 13: 0599-0611
    CrossrefPubMedGoogle Scholar
  • 36 Ragot T, Vincent N, Chafey P, Vigne E, Gilgenkrantz H, Couton D, Cartaud J, Briand P, Kaplan J-C, Perricaudet M, Kahn A. Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature 1993; 361: 0647-0650
    CrossrefPubMedGoogle Scholar
  • 37 Nadal-Ginard B, Nguyen HT, Madhavi V. Induction of muscle specific genes in the absence of commitment is reversible. Exp Biol Med 1984; 9: 0250-0259
    PubMedGoogle Scholar
  • 38 Shani M, Zevin-Sonkin D, Saxel D, Carmon Y, Catcoff D, Nudel U, Yaffe D. The correlation between the synthesis of skeletal muscle actin, myosin heavy chain, and myosin light chain and the accumulation of corresponding mRNA sequences during myogenesis. Dev Biol 1981; 111: 0324-0334
    PubMedGoogle Scholar
  • 39 Nadal-Ginard B. Commitment, fusion and biochemical differentation on a myogenic cell line in the absence of DNA synthesis. Cell 1978; 15: 0855-0864
    CrossrefPubMedGoogle Scholar
  • 40 Endo T, Nadal-Ginard B. Three types of muscle-specific gene expression in fusion-blocked rat skeletal muscle cells: Translational control in EGTA-treated cells. Cell 1987; 49: 0515-0526
    CrossrefPubMedGoogle Scholar
  • 41 Miranda AF, Nette EG, Khan S, Brockbank K, Schonberg M. Alteration of myoblast phenotype by dimethylsulfoxide. Proc Natl Acad Sci USA 1978; 83: 8511-8515
    PubMedGoogle Scholar
  • 42 Blau HM, Epstein ChJ. Manipulation of myogenesis in vitro: Reversible inhibition by DMSO. Cell 1979; 17: 0095-0108
    CrossrefPubMedGoogle Scholar
  • 43 Strauch AR, Offord JD, Chalkley R, Rubinstein PA. Characterization of actin mRNA levels in BC3H1 cell differentiation. J Biol Chem 1986; 261: 0849-0855
    PubMedGoogle Scholar
  • 44 Strauch A, Rubinstein PA. Induction of vascular smooth muscle alpha-iso-actin expression in BC3H1 cells. J Biol Chem 1984; 259: 3152-3159
    PubMedGoogle Scholar
  • 45 Reznikoff CA, Brankow DW, Heidelberger C. Establishment and characterization of a cloned line of C3H mouse embryo cells sensitive to postconfluence inhibition of division. Cancer Res 1977; 33: 3231-3238
    PubMedGoogle Scholar
  • 46 Taylor SM, Jones PA. Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. Cell 1979; 17: 0771-0779
    CrossrefPubMedGoogle Scholar
  • 47 Choi J, Costa ML, Mermelstein CS, Chagas C, Holtzer S, Holtzer H. MyoD converts primary dermal fibroblast, chondroblast, smooth muscle, and retinal pigmented epithelial cells into striated mononucleated myoblasts and multinucleated myotubes. Proc Natl Acad Sci USA 1990; 87: 7988-7992
    CrossrefPubMedGoogle Scholar
  • 48 Barlovatz-Meimon G, Frisdal E, Bassaglia Y, Hantai D, Angles-Cano E, Gautron J. Relationship between plasminogen activators and regeneration capacities of rat skeletal muscles. In: Serine proteases and their serpin inhibitors in the nervous system. Festoff BW. ed. Plenum Press; New York: 1990. pp 0229-0241
    CrossrefGoogle Scholar
  • 49 Couch CB, Strittmatter WJ. Rat myoblast fusion requires metalloendoprotease activity. Cell 1983; 32: 0257-0265
    CrossrefPubMedGoogle Scholar
  • 50 Yagami-Hiromasa T, Sato T, Kurisaki T, Kamijo K, Nabeshima Y-I, Fujisawa-Sehara A. A metalloprotease-disintegrin participating in myoblast fusion. Nature 1995; 377: 0652-0656
    CrossrefPubMedGoogle Scholar
  • 51 Gogos JA, Thompson R, Lowry W, Sloane BF, Weintraub H, Horwitz M. Gene trapping in differentiating cells lines: Regulation of the lysosomal protease cathepsin B in skeletal myoblast growth and fusion. J Cell Biol 1996; 134: 0837-0847
    CrossrefPubMedGoogle Scholar
  • 52 Guerin CW, Holland PC. Synthesis and secretion of matrix-degrading met-alloproteases by human skeletal muscle satellite cells. Dev Dynam 1995; 202: 0091-0099
    CrossrefPubMedGoogle Scholar
  • 53 Schafer BW, Blakely BT, Darlington GJ, Blau HM. Effect of cell history on response to helix-loop-helix family of myogenic regulators. Nature 1990; 344: 0454-0458
    CrossrefPubMedGoogle Scholar
  • 54 Lassar A, Munsterberg A. Wiring diagrams: Regulatory circuits and the control of skeletal myogenesis. Curr Opin Cell Biol 1994; 6: 0432-0442
    CrossrefPubMedGoogle Scholar
  • 55 Lassar AB, Skapek SX, Novitch B. Regulatory mechanisms that coordinate skeletal muscle differentiation and cell cycle withdrawal. Curr Opin Cell Biol 1994; 6: 0788-0794
    CrossrefPubMedGoogle Scholar
  • 56 Brunner G, Schirrmacher V. Fibrin autography of plasminogen activator by electrophoretic transfer into fibrin agar gels. Anal Biochem 1988; 168: 0411-0416
    CrossrefPubMedGoogle Scholar